OligoNova Hub, the new national platform for oligonucleotide drug development, and part of SciLifeLab’s Drug Discovery and Development (DDD) platform, has opened a call for collaborative projects. Academic scientists at Swedish universities with project ideas for new therapeutic oligonucleotides are welcome to apply. The drug idea will be developed in close collaboration between the academic laboratory and drug discovery experts at the DDD platform at SciLifeLab and OligoNova Hub. The call closes on May 13.

More information about the call and how to apply can be found on the homepages of SciLifeLab’s DDD platform and OligoNova.

A digital information meeting about this call will be held April 4, 2022 at 14.00–15.00.

OligoNova Hub, enabled through funding from the Knut and Alice Wallenberg Foundation, SciLifeLab, the University of Gothenburg and private donations, will bring a new set of tools into the hands of Swedish researchers to help them turn their ideas and academic discoveries into more effective therapies. A third pillar of therapeutic oligonucleotides are thereby added to the current operations of the DDD platform on small molecules and protein drugs.